Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SHR-1139 in plaque psoriasis with inadequate response to prior biologic therapy
CTR20262906Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2026
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1139 in plaque psoriasis, sponsored by Hengrui Therapeutics. Started Jul 2026; status: active.
02
Drugs
SHR-1139
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20262906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262906.